We used quantitative proton magnetic resonance spectroscopy (1H-MRS) to evaluate mean relative concentrations ratios for NAA, Cr, Cho and mI during the study of cervical spinal cord plaques in a relapsing-remitting multiple sclerosis (RRMS). A cervical spine MR exam was repeated five times on the following days for two months starting from the onset of a relapse phase, using a 3T whole-body system, with the voxel placed along the demyelinazation lesion. The quantification results were compared with the healthy metabolites content. Quantitative cervical spectroscopy is a reliable tool and can offer important metabolic information as already used on the brain to evaluate the severity, progression and pathogenesis of multiple sclerosis.
NarayanaPA: Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging15: 46S–56S, 2005.
2.
BhakooKKPearceD: In vitro expression of N-acetyl aspartate by oligodendrocytes: Implications for proton magnetic resonance spectroscopy signal in vivo. J Neurochem74: 254–262, 2000.
3.
JungREYeoRAChiulliSJ: Biochemical markers of cognition: a Proton MR spectroscopy study of normal human brain. Neuroreport10: 3327–3331, 1999.
LearySMDavieCAParkerGJ: 1H magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis. J Neurol246: 1023–1026, 1999.
6.
De StefanoNMatthewsPMAntelJP: Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol38: 901–909, 1995.
7.
ArnoldDLMatthewsPMFrancisGS: Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol31: 235–241, 1992.
8.
CastilloMSmithJKKwockL: Correlation of myo-inositol levels and grading of cerebral astrocytomas. Am J Neuroradiol21: 1645–1649, 2000.
9.
Saraf-LaviEBowenBCPattanyPM: Proton MR spectroscopy of gliomatosis cerebri: Case report of elevated myoinositol with normal choline levels. Am J Neuroradiol24: 782–784, 2003
10.
VrenkenHBarkhofFUitdehaagBM: Spectroscopic evidence for glial increase but not for neuro- axonal damage in MS normal-appearing white matter. Magn Reson Med53: 256–266, 2005.
11.
FernandoKTMcLeanMAChardDT: Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain127: 1361–9, 2004.
12.
BitschABruhnHVougioukasV: Inflammatory CNS demyelination: Histopathologic correlation with in vivo quantitative proton MR spectroscopy. Am J Neuroradiol20: 1619–27, 1999.
13.
KendiATKTanFUKendiM: MR spectroscopy of cervical spinal cord in patients with multiple sclerosis. Neuroradiology46: 764–769, 2004.
14.
HenningAScharMKolliasSS: Quantitative magnetic resonance spectroscopy in the entire human cervical spinal cord and beyond at 3T. Magn Reson Med published on line 2008.
15.
MarlianiAFClementiVAlbini RiccioliL: Quantitative proton magnetic resonance spectroscopy of the human cervical spinal cord at 3 Tesla. Magn Reson Med57: 160–3, 2007.
16.
ProvencherSW: Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med30: 672–679, 1993.
17.
DavieCABarkerGJWebbS: Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain117: 49–58, 1994.
18.
DavieCAHawkinsCPBarkerGJ: Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain117: 49–58, 1994.
19.
NarayanaPADoyleTJLaiD: Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol43: 56–71, 1998.
